TNFAIP3 and insomnia measurement: These findings advance a paradigm shift in comorbidity management: rather than treating COPD and insomnia as distinct entities, we identified therapeutic agents targeting their common TNFAIP3-centered interactome to disrupt the inflammation-sleep disruption cycle through single-agent polypharmacology.